8-hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 4, Issue 3, 2011, Pages 267-275

  Soini, Ylermi ^a,b   Haapasaari, Kirsi Maria ^c   Vaarala, Markku H ^d   Turpeenniemi Hujanen, Taina ^c   Karja V ^b   Karihtala, Peeter ^c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Carcinoma; Keap1; Nrf2; Oxidative stress; Peroxiredoxin; Urinary bladder

Indexed keywords

3 NITROTYROSINE; 3-NITROTYROSINE; 8 HYDROXYDEOXYGUANOSINE; 8-HYDROXY-2'-DEOXYGUANOSINE; DEOXYGUANOSINE; DRUG DERIVATIVE; KEAP1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; PEROXIREDOXIN; SIGNAL PEPTIDE; THIOREDOXIN; TRANSCRIPTION FACTOR NRF2; TUMOR MARKER; TYROSINE;

ARTICLE; BLADDER TUMOR; CARCINOMA; CELL NUCLEUS; CYTOPLASM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NONPARAMETRIC TEST; OXIDATIVE STRESS; PHYSIOLOGY; PROGNOSIS;

CARCINOMA; CELL NUCLEUS; CYTOPLASM; DEOXYGUANOSINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PEROXIREDOXINS; PROGNOSIS; STATISTICS, NONPARAMETRIC; THIOREDOXINS; TUMOR MARKERS, BIOLOGICAL; TYROSINE; URINARY BLADDER NEOPLASMS;

EID: 80051609028     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Eble JN, Sauter G, Epstein JI, Sesterhenn I. Tumours of the Urinary System and Male Genital Organs. WHO Classification of tumours. IARC Press, Lyon, France, 2004.
2. Itoh K, Mimura J, Yamamoto M. Discovery of the Negative Regulator of Nrf2, Keap1: A Historical Overview. Antioxid Redox Signal. 2010 (in press)
3. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 2008;58:262-70.
4. Karihtala P, Soini Y. Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS 2007;115:81-103.
5. Karihtala P, Soini Y, Vaskivuo L, Bloigu R, Puistola U. DNA adduct 8-hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma. Int J Gynecol Cancer 2009;19:1047-51.
6. Murtas D, Piras F, Minerba L, Ugalde J, Floris C, Maxia C, Demurtas P, PerraMT, Sirigu P. Nuclear 8-hydroxy-2'-deoxyguanosine as survival biomarker in patients with cutaneous melanoma. Oncol Rep 2010 Feb;23(2):329-35.
7. Sheridan J, Wang LM, Tosetto M, Sheahan K, Hyland J, Fennelly D, O'Donoghue D, Mulcahy H, O'Sullivan J. Nuclear oxidative damage correlates with poor survival in colorectal cancer. Br J Cancer 2009 Jan 27;100(2):381-8
8. Zhang B, Wang Y, Su Y. Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett 2009;286:154-60.
9. Knoops B, Loumaye E, Van Der Eecken V. Evolution of the peroxiredoxins. Subcell Biochem 2007; 44: 27-40
10. Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, Soini Y. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma J Pathol 2002; 196: 316-323
11. Barranco-Medina S, Lázaro JJ, Dietz KJ. The oligomeric conformation of peroxiredoxins links redox state to function. FEBS Lett 2009;583:1809-16.
12. Sova H, Jukkola-Vuorinen A, Puistola U, Kauppila S, Karihtala P. 8-Hydroxydeoxyguanosine: a new potential independent prognostic factor in breast cancer. Br J Cancer 2010;102:1018-23.
13. Pylväs M, Puistola U, Kauppila S, Soini Y, Karihtala P. Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis. Eur J Cancer 2010;46:1661-7.
14. Shen J, Deininger P, Hunt JD, Zhao H. 8-Hydroxy -2'-deoxyguanosine (8-OH-dG) as a potential survival biomarker in patients with nonsmallcell lung cancer. Cancer 2007;109:574-80.
15. Yao QH, Mei SR, Weng QF, Zhang PD, Yang Q, Wu CY, Xu GW. Determination of urinary oxidative DNA damage marker 8-hydroxy-2'-deoxyguanosine and the association with cigarette smoking. Talanta 2004;63:617-23.
16. Lee SU, Rhee M, Min YK, Kim SH. Involvement of peroxiredoxin IV in the 16alphahydroxyestrone-induced proliferation of human MCF-7 breast cancer cells. Cell Biol Int 2008;32:401-5.
17. Jin DY, Chae HZ, Rhee SG, Jeang KT. Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation. J Biol Chem 1997;272:30952-61.
18. Wang HQ, Du ZX, Liu BQ, Gao YY, Meng X, Guan Y, Zhang HY. TNF-related apoptosis-inducing ligand suppresses PRDX4 expression. FEBS Lett 2009;583:1511-5.
19. Steele LP, Georgopoulos NT, Southgate J, Selby PJ, Trejdosiewicz LK. Differential susceptibility to TRAIL of normal versus malignant human urothelial cells. Cell Death Differ 2006;13:1564-76.
20. Kresowik TP, Griffith TS. Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy 2009;1:281-8.
21. Karihtala P, Mäntyniemi A, Kang SW, Kinnula VL, Soini Y. Peroxiredoxins in breast carcinoma. Clin Cancer Res 2003;9:3418-24.
22. Zaharieva B, Simon R, Ruiz C, Oeggerli M, Mihatsch MJ, Gasser T, Sauter G, Toncheva D. High-throughput tissue microarray analysis of CMYC amplificationinurinary bladder cancer. Int J Cancer 2005;117:952-6.
23. Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, Soini Y. Overexpression of peroxiredoxins I, II, III, V, and VI in malignantmesothelioma. J Pathol 2002;196: 316-23.
24. Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R, Manevich Y, Beeson C, Neumann CA. Prdx1 inhibits tumorigenesis via regulating PTEN/AKTactivity. EMBO J 2009;28:1505-17
25. Quan C, Cha EJ, Lee HL, Han KH, Lee KM, Kim WJ. Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol 2006;175:1512-6.
26. Lukosz M, Jakob S, Büchner N, Zschauer TC, Altschmied J, Haendeler J. Nuclear redox signaling. Antioxid Redox Signal 2010;12:713-42.
27. Yokomizo A, Ono M, Nanri H, Makino Y, Ohga T, Wada M, Okamoto T, Yodoi J, Kuwano M, Kohno K. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 1995;55:4293-6.
28. Watson WH, Yang X, Choi YE, Jones DP, Kehrer JP. Thioredoxin and its role intoxicology. Toxicol Sci 2004;78:3-14..
29. Holmgren A, Lu J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Commun 2010;396:120-4.
30. Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal 2010;13:1665-78.
31. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY, Eom HS, Yoo NJ, Lee SH. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 2010;220:446-51.
32. Iida K, Itoh K, Maher JM, Kumagai Y, Oyasu R, Mori Y, Shimazui T, Akaza H, Yamamoto M. Nrf2 and p53 cooperatively protect against BBNinduced urinarybladder carcinogenesis. Carcinogenesis 2007;28:2398-403.